home / stock / advm / advm articles

ADVM Articles, Adverum Biotechnologies Inc. - From 02/28/24

Stock Information
Company Name: Adverum Biotechnologies Inc.
Stock Symbol: ADVM
Market: NASDAQ
Website: adverum.com
Menu
ADVM ADVM Quote ADVM Short ADVM News ADVM Articles ADVM Message Board
Get ADVM Alerts

News, Short Squeeze, Breakout and More Instantly...
Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference | Benzinga

REDWOOD CITY, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use...
Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference | Benzinga

REDWOOD CITY, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company that aims to estab...

Why Is Blindness Focused-Adverum Biotechnologies Stock Trading Lower Today? | Benzinga

Adverum Biotechnologies Inc (NASDAQ:ADVM) released preliminary safety and efficacy data from the ongoing LUNA Phase 2 trial in patients with w...

Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session | Benzinga

Shares of Air Products and Chemicals, Inc. (NYSE: APD) fell sharply during Monday’s session after the company reported worse-than-expected fi...
Why Adverum Biotechnologies Stock Is Trading Higher | Benzinga

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) shares are trading higher Monday after the company announced that it has agreed to sell approximately 1...

Adverum Biotechnologies Announces $127.5 Million Private Placement Financing | Benzinga

- Financing led by TCGX with participation from new and existing investors including 5AM Ventures, Commodore Capital, Frazier Life Sciences, Logos...

Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024 | Benzinga

- Preliminary safety and efficacy data from ongoing LUNA Phase 2 study of Ixo-vec for the treatment of wet AMD will be presented at the 47th Annua...
Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer | Benzinga

REDWOOD CITY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company that aims to estab...

Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society | Benzinga

REDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company that aims to estab...

Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference | Benzinga

REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company that aims to estab...
Previous 10 Next 10